William Gerber

Bio

William Gerber, MD, is an Investment Partner at Bay City Capital and has been with the firm since September 1999. He was most recently President and Chief Executive Officer of Epoch BioSciences, which was acquired by Nanogen in 2004. Prior to joining Epoch, Dr. Gerber served as President and Chief Executive Officer of diaDexus LLC, a joint venture established by Incyte Pharmaceuticals and SmithKline Beecham to apply genomics to the discovery of novel diagnostic products. Dr. Gerber previously served as Vice President and Chief Operating Officer of Onyx Pharmaceuticals, as President of Chiron Diagnostics, and as Senior Vice President and General Manager of the PCR Division of Cetus Corporation. Dr. Gerber is a member of the board of directors of Aviir, Inc., Conatus Pharmaceuticals, NexusDx, Sangamo Biosciences and Vivaldi Biosciences. He also served on and was President of the Board of Medical Quality Assurance, State of California. He received his MD and BS degrees from University of California, San Francisco Medical Center.